50 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Feb 09
Regulation FD Disclosure
12:00am
foundation
Commitment to driving shareholder value and to transparency on the business
with goal to drive strong cash flow and earnings
Ligand … and transparency with investors
Prolific drug discovery engine has produced multitudes of drug candidates
Objectives communicated and major goals achieved
Strong
425
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
10 Sep 09
Business combination disclosure
12:00am
Cost-efficient R&D business with tight spending discipline
Clear communication and transparency with investors
Clarity on how to drive a business … forward in this market environment
Commitment to driving shareholder value and to transparency on the business
with goal to drive strong cash flow
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
10 Sep 09
Business Development and Strategic Planning
12:00am
Cost-efficient R&D business with tight spending discipline
Clear communication and transparency with investors
Clarity on how to drive a business … forward in this market environment
Commitment to driving shareholder value and to transparency on the business
with goal to drive strong cash flow
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
6 Sep 05
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
with electronic
and print products and information services designed to improve the transparency
of the over-the-counter (OTC) markets. The products
425
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Sep 08
Business combination disclosure
12:00am
and to transparency on the business with goal to drive strong cash flow and earnings
8 Combined Product Pipeline Stage of Development Product Indication Partner
8-K
EX-99.1
10f5u1lz1sjl2afr31r5
24 Sep 08
1 Joseph A. Mollica, Ph.D., Chairman of the Board, Interim President & CEO, Pharmacopeia John L. Higgins, President & CEO
12:00am
425
EX-99.2
c3rl2 q0sq
25 Sep 08
Business combination disclosure
12:00am
8-K
EX-99.2
4n1f7tjdh6f7dlcm0
24 Sep 08
1 Joseph A. Mollica, Ph.D., Chairman of the Board, Interim President & CEO, Pharmacopeia John L. Higgins, President & CEO
12:00am
425
EX-99.1
iepj2xw9 wd
25 Sep 08
Business combination disclosure
12:00am
425
EX-99.2
vmdsans4
24 Sep 08
Business combination disclosure
12:00am
425
nblp7ku s287
3 Nov 08
Business combination disclosure
12:00am
425
cot 0pu8yk6sl6xhi73a
12 Nov 08
Business combination disclosure
12:00am
425
EX-99.1
3ahxy0ak9f
3 Nov 08
Business combination disclosure
12:00am
425
EX-99.1
4nlsmo9url ffuj3z3
12 Nov 08
Business combination disclosure
12:00am
425
EX-99.1
z8vm5qiidtwb58lrvn
26 Sep 08
Business combination disclosure
12:00am
8-K
EX-99.1
nr3u99agaeheuj9j
25 Sep 08
Ligand to Acquire Pharmacopeia Webcast
12:00am
425
4suu3dsn7x5
25 Sep 08
Business combination disclosure
12:00am
8-K
EX-10.2
gr0xzzcrz6 df8oil7
18 Aug 14
Entry into a Material Definitive Agreement
12:00am